Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

LCTX
Lineage Cell Therapeutics, Inc.US flagAMEX
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Mr. Brian M. Culley M.A., M.B.A.
Full Time Employees
68
Sector
Healthcare
Industry
Biotechnology
Address
2173 Salk Avenue Carlsbad CA United States of America 92008
IPO Date
Mar 5, 1992
Similar Companies
Business
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Company News

  • Insiders Are Scooping Up These 5 Stocks Now

  • Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?

  • Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

  • Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround

  • Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

  • Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

  • Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript

  • Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

  • Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

  • What Makes Lineage Cell (LCTX) a New Buy Stock

  • OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

  • Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript

  • Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates

  • Lineage to Present at 2024 BIO International Convention

  • Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

  • Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript

  • Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

  • Lineage Announces Changes to Board of Directors

  • Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

  • RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit